









Markets
/
Stocks
/
nasdaq-rgc
/

Regencell Bioscience Holdings Ltd

RGC

16.810USD

-1.630-8.84%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

8.31BMarket Cap

--P/E TTM



Regencell Bioscience Holdings Ltd

16.810

-1.630-8.84%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Regencell Bioscience Holdings Ltd

Currency: USD Updated: 2025-10-09

Key Insights

Its valuation is considered undervalued,and institutional recognition is low. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Regencell Bioscience Holdings Ltd's Score

Industry at a Glance

Industry Ranking

307 / 502

Overall Ranking

596 / 4699

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Regencell Bioscience Holdings Ltd Highlights

StrengthsRisks

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Undervalued

The company’s latest PE is -105.06, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 680.91K shares, increasing 32.86% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-09

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Regencell Bioscience Holdings Ltd's Company Valuation

Currency: USD Updated: 2025-10-09

The company’s current valuation score is 1.00, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -105.06, which is -100.00% below the recent high of 0.00 and -4655.96% above the recent low of -4996.58.

Score

Industry at a Glance

Previous score

1.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 307/502

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-09

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-09

The company’s current price momentum score is 8.88, which is higher than the Biotechnology & Medical Research industry's average of 7.18. Sideways: Currently, the stock price is trading between the resistance level at 22.37 and the support level at 13.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.11

Change

-0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

1.288

Neutral

RSI(14)

48.683

Neutral

STOCH(KDJ)(9,3,3)

43.481

Sell

ATR(14)

1.430

High Vlolatility

CCI(14)

38.183

Neutral

Williams %R

60.465

Sell

TRIX(12,20)

1.062

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

18.390

Sell

MA10

17.287

Sell

MA20

16.147

Buy

MA50

14.464

Buy

MA100

123.079

Sell

MA200

85.221

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-09

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Au (Yat-Gai)

437.90M

+2.69%

Digital Mobile Venture, Ltd.

37.58M

Geode Capital Management, L.L.C.

391.07K

+50.99%

Squarepoint Capital LLP

99.84K

Schonfeld Strategic Advisors LLC

52.10K

BNP Paribas Securities Corp. North America

45.05K

UBS Financial Services, Inc.

37.53K

Morgan Stanley & Co. LLC

32.42K

+16965.79%

Y-Intercept (Hong Kong) Ltd

13.04K

BlackRock Financial Management, Inc.

4.87K

-46.21%

Risk Assessment

Currency: USD Updated: 2025-10-09

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.48. The company's beta value is 2.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.